Members‎ > ‎

Professor Steven Kelly DSc IWAF FRSB FRSC FLSW



Sewell TR, Hawkins NJ, Stotz HU, Huang YJ, Kelly SLKelly DE, Fraaije B, Fitt BDL. Azole sensitivity in Leptosphaeria pathogens of oilseed rape: the role of lanosterol 14alpha-demethylase. Scientific Reports. 2017, 7:15849.

Butts A, DeJarnette C, Peters TL, Parker JE, Kerns ME, Eberle KE, Kelly SL, Palmer GE. Target abundance-based fitness screening (TAFiS) facilitates rapid identification of target-specific and physiologically active chemical probes. mSphere. 2017, DOI: 10.1128/mSphere.00379-17. 

Hull CMWarrilow AGSRolley NJPrice CL, Donnison IS, Kelly DEKelly SL. Co-production of 11alpha-hydroxyprogesterone and ethanol using recombinant yeast expressing fungal steroid hydroxylases. Biotechnol Biofuels. 2017, 10:226.

Rybak JM, Dicken CM, Parker JE, Caudle K, Manigaba K, Whaley SG, Nishimoto A, Luna-Tapia A, Roy S, Zhang Q, Barker KS, Palmer GE, Sutter TR, Homayouni R, Wiederhold NP, Kelly SL, Rogers PD. Loss of C-5 sterol desaturase activity results in increased resistance to azole abd echinocandin antifungals in a clinical isolate of Candida parapsilosis. Antimicrobial Agents and Chemotherapy. 2017, doi: 10.1128/AAC.00651-17.

Warrilow AGS, Parker JE, Price CL, Garvey EP, Hoekstra WJ, Schotzinger RJ, Wiederhold NP, Nes WD, Kelly DE, Kelly SL. The tetrazole VT-1161 is a potent inhibitor of Trichophyton rubrum through its inhibition T. rubrum CYP51. Antimicrobial Agents and Chemotherapy. 2017, EPub ahead of print.

Colley T, Alanio A, Kelly SL, Sehra G, Kizawa Y, Warrilow AGS, Parker JE, Kelly DE, Kimura G, Anderson-Dring L, Nakaoki T, Sunose M, Onions S, Crepin D, Lagasse F, Crittall M, Shannon J, Cooke M, Bretagne S, King-Underwood J, Murray J, Ito K, Strong P, Rapeport G. In vitro and in vivo antifungal profile of a novel and long acting inhaled azole PC945, on Aspergillus fumigatus infection. Antimicrobial Agents and Chemotherapy. 2017, doi:10.1128/AAC.02280-16.


McCourt P, Liu H-Y, Parker JE, Gallo-Ebert C, Donigan M, Bata A, Giordano C, Kelly SL, Nickels Jr JT. Proper sterol distribution is required for Candida albicans hyphal formation and virulence. G3: Genes, Genomes, Genetics. 2016, doi: 10.1534/g3.116.033969.

Warrilow AG, Price CL, Parker JE, Rolley NJ, Smyrniotis CJ, Hughes DD, Thoss V, Nes WD, Kelly DE, Holman TR, Kelly SL. Azole antifungal sensitivity of sterol 14α-demethylase (CYP51) and CYP5218 from Malassezia globosa. Scientific Reports. 2016, 6, 27690.

Warrilow AG, Parker JE, Price CL, Nes WD, Garvey EP, Hoekstra WJ, Schotzinger RJ, Kelly DE, Kelly SL. The invesitgational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrobial Agents and Chemotherapy. 2016, 60(8), 4530-4538.


Warrilow AGS, Parker JE, Price CL, Nes WD, Kelly SL, Kelly DE. CYP51-mediated azole resistance in Aspergillus fumigatus: an in vitro biochemical study. Antimicrobial Agents and Chemotherapy. 2015, 59(12), 7771-7778.

Berkow El, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD. Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrobial Agents and Chemotherapy. 2015, 59(10), 5942-5950.

Derbyshire MC, Michaelson L, Parker J, Kelly S, Thacker U, Powers SJ, Bailey A, Hammond-Kosack K, Courbot M, Rudd J. Analysis of cytochrome b5 reductase-mediated metabolism in the phytopathogenic fungus Zymoseptoria tritici reveals novel functionalities implicated in virulence. Fungal Genetics and Biology. 2015, 82, 69-84.

Lamb DC, Warrilow AG, Rolley NJ, Parker JE, Nes WD, Smith SN, Kelly DE, Kelly SL. Azole antifungal agents to treat the human pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through inhibition of sterol 14alpha-demethylase (CYP51). Antimicrobial Agents and Chemotherapy. 2015, 59(8), 4707-4713.

Price CL, Parker JE, Warrilow AGS, Kelly DE, Kelly SL. Azole fungicides - understanding resistance mechanisms in agricultural fungal pathogens. Pest Management Science. 2015, 71(8), 1054-1058.

Price CL, Warrilow AGS, Parker JE, Mullins JGL, Nes WD, Kelly DE, Kelly SL. Novel substrate specificity and temperature sensitive activity of Mycosphaerella graminicola CYP51 (MgCYP51) supported by the native NADPH cytochrome P450 reductase (CPR). Applied and Environmental Microbiology. 2015, 81(10), 3379-3386.


Salvage R, Hull CM, Kelly DE, Kelly SL. Use of 70% alcohol for the routine removal of microbial hard surface bioburden in life science cleanrooms. Future Microbiology. 2014, 9(10), 1123-1130.

Hull CM, Loveridge EJ, Donnison IS, Kelly DE, Kelly SL. Co-production of bioethanol and probiotic yeast biomass from agricultural feedstock: application of the rural biorefinery concept. AMB Express. 2014, 4, Epub.

Hull CM, Loveridge EJ, Rolley NJ, Donnison IS, Kelly SL, Kelly DE. Co-production of ethanol and squalene using a Saccharomyces cerevisiae ERG1 (squalene epoxidase) mutant and agro-industrial feedstock. Biotechnology for Biofuels. 2014, 7, Epub.

Warrilow AGS, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrobial Agents and Chemotherapy. 2014, Epub.

Parker JE, Warrilow AGS, Price CL, Mullins JGL, Kelly DE, Kelly SL. Resistance to antifungals that target CYP51. Journal of Chemical Biology. 2014, 7(4), 143-161. 

Warrilow AGS, Hull CM, Rolley NJ, Parker JE, Nes WD, Smith SN, Kelly DE, Kelly SL. Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasitica through inhibition of sterol 14alpha-demethylase (CYP51). Applied and Environmental Microbiology. 2014. 80(19), 6154-6166.

Hawkins NJ, Cools HJ, Sierotzki H, Shaw MW, Knogge W, Kelly SL, Kelly DE, Fraaije BA. Paralog re-emergence: a novel, historically contingent mechanism in the evolution of antimicrobial resistance. Molecular Biology and Evolution. 2014, 31(7), 1793-1802.

Carter HE, Fraaije BA, West JS, Kelly SL, Mehl A, Shaw MW, Cools HJ. Alterations in the predicted regulatory and coding regions of the sterol 14alpha-demethylase gene (CYP51) confer decreased azole sensitivity in the oilseed rape pathogen Pyrenopeziza brassicae. Molecular Plant Pathology 2014, 15(5), 513-522.


Reid EL, Weynberg KD, Love J, Isupov MN, Littlechild JA, Wilson WH, Kelly SL, Lamb DC, Allen, MJ. Functional and structural characterisation of a viral cytochrome b5. FEBS Letters 2013, 587(22), 3633-3639.

Eddouzi J, Parker JE, Vale-Silva LA, Coste A, Ischer F, Kelly S, Manai M, Sanglard D. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrobial Agents and Chemotherapy. 2013, 57(7), 3182-3193.

Hoobler EK, Rai G, Warrilow AGS, Perry SC, Smyrniotis CJ, Jadhav A, Simeonov A, Parker JE, Kelly DE, Maloney DJ, Kelly SL, Holman TR. Discovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy. PLoS One. 2013, 8(6), e65928.

Belic A, Pompon D, Monostory K, Kelly D, Kelly S, Rozman, D. An algorithm for rapid computational construction of metabolic networks: A cholesterol biosynthesis example. Computers in Biology and Medicine. 2013, 43(5), 471-480.

Calabrese EC, Castellano S, Santoriello M, Sgherri C, Quartacci MF, Calucci L, Warrilow AGS, Lamb DC, Kelly SL, Milite C, Granata I, Sbardella G, Stefancich G,Maresca B, Porta A. Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans. Journal of Antimicrobial Chemotherapy. 2013, 68(5), 1111-1119.

Fan JR, Urban M, Parker JE, Brewer HC, Kelly SL, Hammond-Kosack KE, Fraaije BA, Liu XL, Cools HJ. Characterization of the sterol 14 alpha-demethylases of Fusarium graminearum identifies a novel genus-specific CYP51 function. New Phytologist. 2013, 198(3), 821-835.

Parker JE, Warrilow AG, Cools HJ, Fraaije BA, Lucas JA, Rigdova K, Griffiths WJ, Kelly DE, KellySL. Prothioconazole and prothioconazole-desthio activity against Candida albicans sterol 14 alpha-demethylase (CaCYP51). Applied and Environmental Microbiology. 2013, 79(5), 1639-1645.

Kelly SL, Kelly DE. Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us? Philosophical Transactions of the Royal Society B 2013, 368(1612)SI, Art. No. 20120476.

Warrilow AG, Parker JE, Kelly DE, Kelly SL. Azole affinity of sterol 14 alpha-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrobial Agents and Chemotherapy. 2013, 57(3), 1352-1360.

Newsome AW, Nelson D, Corran A, Kelly SL, Kelly DE. The cytochrome P450 complement (CYPome) of Mycosphaerella graminicola. Biotechnology and Applied Biochemistry. 2013, 60(1), 52-64.


Hull CM, Bader O, Parker JE, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrobial Agents and Chemotherapy. 2012, 56(12), 6417-6421.

Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, KellySL. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrobial Agents and Chemotherapy. 2012, 56(8), 4223-4232.

Zhao B, Moody SC, Hider RC, LeiL, Kelly SL, Waterman MR, Lamb DC. Structural Analysis of cytochrome P450 105N1 involved in the biosynthesis of the zincophore Coelibactin. International Journal of Molecular Sciences. 2012, 13(7), 8500-8513.

Vale-SilvaLA, Coste AT, Ischer F, Parker JE, Kelly SL, Pinto E, Sanglard D. Azole resistance by loss of function of the sterol delta-5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrobial Agents and Chemotherapy. 2012, 56(4), 1960-1968.

Warrilow AGS, Mullins JGL, Hull CM, Parker JE, Lamb DC, Kelly DE, Kelly SL. S279 point mutations in Candida albicans sterol 14-alpha demethylase (CYP51) reduces in vitro inhibition by fluconazole. Antimicrobial Agents and Chemotherapy. 2012, 56(4), 2099-2107.

Moody SC, Zhao B, Lei L, Nelson DR, Mullins JG, Waterman MR, Kelly SL, Lamb DC. Investigating conservation of the albaflavenone biosynthetic pathway and CYP170 bifunctionality in streptomycetes. FEBS Journal. 2011, 279(9), 1640-1649.

Agnew CRJ, Warrilow AGS, Burton NM, Lamb DC, Kelly SL, Brady RL. An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae. Antimicrobial Agents and Chemotherapy.2012, 56(2), 391-402.

Higgins J, Pinjon E, Oltean HN, White TC, Kelly SL, Martel CM, Sullivan DJ, Coleman DC, Moran GP. Triclosan antagonizes fluconazole activity against Candida albicans. Journal of Dental Research 2012, 91(1), 65-70.


Cools HJ, Mullins JGL, Fraaije BA, Parker JE, Kelly DE, Lucas JA, Kelly SL. Impact of recently emerged sterol 14 alpha-demethylase (CYP51) variants of Mycosphaerella graminicola on azole fungicide sensitivity. Applied and Environmental Microbiology. 2011, 77(11), 3830-3837.

Parker JE, Warrilow AGS, Cools HJ, Martel CM, Nes, WD, Fraaije BA, Lucas JA, Kelly DE, Kelly SL. Mechanism of binding of prothioconazole to Mycosphaerella graminicola CYP51 differs from that of other azole antifungals. Applied and Environmental Microbiology. 2011, 77(4), 1460-1465.

Martel CM, Parker JE, Jackson CJ, Warrilow AGS, Rolley N, Greig C, Morris SM, Donnison IS, Kelly DE, Kelly SL. Expression of bacterial levanase in yeast enables simultaneous saccharification and fermentation of grass juice to bioethanol. Bioresource Technology. 2011, 102(2), 1503-1508.


Cheng Q, Lamb DC, Kelly SL, Lei L, Guengerich FP. Cyclization of a cellular dipentaenone by Streptomyces coelicolor cytochrome P450 154A1 without oxidation/reduction. Journal of the American Chemical Society 2010, 132(43), 15173-15175.

Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AGS, Rolley N, Kelly DE, Kelly SL. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrobial Agents and Chemotherapy. 2010, 54(11), 4527-4533.

Martel CM, ParkerJE, Warrilow AGS, Rolley N, Kelly SL, Kelly, DE. Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14 alpha-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B. Antimicrobial Agents and Chemotherapy. 2010, 54(11), 4920-4923.

Warrilow AGS, Melo N, Martel CM, Parker JE, Kelly SL, Kelly DE. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. Antimicrobial Agents and Chemotherapy. 2010, 54(10), 4225-4234.

Warrilow AGS, Martel CM, Parker JE, Melo N, Lamb DC, Nes D, Kelly DE, Kelly SL. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrobial Agents and Chemotherapy. 2010, 54(10), 4235-4245.

Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AGS, Kelly DE, Kelly SL. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14 alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrobial Agents and Chemotherapy. 2010, 54(9), 3578-3583.

Cools HJ, Parker JE, Kelly DE, Lucas JA, Fraaije BA, Kelly SL. Heterologous expression of mutated eburicol 14 alpha-demethylase (CYP51) proteins of Mycosphaerella graminicola to assess effects on azole fungicide Sensitivity and intrinsic protein function. Applied and Environmental Microbiology. 2010, 76(9), 2866-2872.

Martel CM, Warrilow AGS, Jackson CJ, Mullins JGL, Togawa RC, Parker JE, Morris MS, Donnison IS, Kelly DE, Kelly SL. Expression, purification and use of the soluble domain of Lactobacillus paracasei beta-fructosidase to optimise production of bioethanol from grass fructans. Bioresource Technology. 2010, 101(12), 4395- 4402.

Lamb DC, Lei L, Zhao B, Yuan H, Jackson CJ, Warrilow AGS, Skaug T, Dyson PJ, Dawson ES, Kelly SL, Hachey DL, Waterman MR. Streptomyces coelicolor A3(2) CYP102 protein, a novel fatty acid hydroxylase encoded as a heme omain without an N-terminal redox partner. Applied and Environmental Microbiology. 2010, 76(6), 1975-1980.


Zhao B, Lei L, Vassylyev DG, Lin X, Cane DE, Kelly SL, Yuan H, Lamb DC, Dawson ES, Waterman MR. Crystal structure of albaflavenone monooxygenase containing a moonlighting terpene synthase active site. Journal of Biological Chemistry.2009, 284(52), 36711-36719.

Jackson CJ, Barton RC, Clark CG, Kelly SL. Molecular characterization of a subgroup IE intron with wide distribution in the large subunit rRNA genes of dermatophyte fungi. Medical Mycology. 2009, 47(6), 609-617.

Lamb DC, Lei L, Warrilow AGS, Lepesheva GI, Mullins JGL, Waterman MR, Kelly SL. The first virally encoded cytochrome P450. Journal of Virology 2009, 83 (16), 8266-8269.

Warrilow AGS, Jackson CJ, Parker JE, Marczylo TH, Kelly DE, Lamb DC, Kelly SL. Identification, characterization and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae. Antimicrobial Agents and Chemotherapy 2009, 53(3) 1157-1164.


Warrilow A, Ugochukwu C, Lamb D, Kelly D, Kelly S. Expression and characterization of CYP51, the ancient sterol 14-demethylase activity for cytochromes P450 (CYP), in the white-rot fungus Phanerochaete chrysosporium. Lipids 2008, 43(12) 1143-1153.

Palabiyik B, Karaer S, Arda N, Toker, SE, Temizkan G, Kelly S, Sarikaya AT. Expression of human cytochrome P450 3A4 gene in Schizosaccharomyces pombe. Biologia 2008, 63(3) 450-454.

Parker JE, Merkamm M, Manning NJ, Pompon D, Kelly SL, Kelly DE. Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus. Antimicrobial Agents and Chemotherapy 2008, 52(10) 3597-3603.

Melo NR, Moran GP, Warrilow AGS, Dudley E, Smith SN, Sullivan DJ, Lamb DC, Kelly DE, Coleman DC, Kelly SL. CYP56 (Dit2p) in Candida albicans: Characterization and investigation of its role in growth and antifungal drug susceptibility. Antimicrobial Agents and Chemotherapy 2008, 52(10) 3718-3724.

La Regina G, D'Auria FD,Tafi A, Piscitelli F, Olla S, Caporuscio F, Nencioni L, Cirilli R, La Torre F, deMelo NR, Kelly SL, Lamb DC, Artico M, Botta M, Palamara AT, Silvestri R. 1-[(3-Aryloxy-3-aryl)propyl]-2H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies. Journal of Medicinal Chemistry 2008, 51(13) 3841-3855.

Jackson CJ, Lamb DC, Warrilow AGS, Parker JE, de Melo NR, Kelly DE, Kelly SL. P450s in microbial sterol biosynthesis and drug targets. Acta Chimica Slovenica 2008, 55(1) 58-62.

Zhao B, Lin X, LeiL, Lamb DC, Kelly SL, Waterman MR, Cane DE. Biosynthesis of the Sesquiterpene Antibiotic Albaflavenone in Streptomyces coelicolor A3(2). Journal of Biological Chemistry 2008, 283(13) 8183-8189.


Chun YJ, ShimadaT, Sanchez-Ponce R, Martin MV, Lei L, Zhao B, Kelly SL, Waterman MR, Lamb DC, Guengerich FP. Electron transport pathway for a Streptomyces cytochrome P450 - Cytochrome P450 105D5-catalyzed fatty acid hydroxylation in Streptomyces coelicolor A3(2). Journal of Biological Chemistry 2007, 282(24) 17486-17500.

Lamb DC, Jackson CJ, Warrilow AG, Manning NJ, Kelly DE, Kelly SL. Lanosterol Biosynthesis in the Prokaryote Methylococcus capsulatus: Insight into the evolution of sterol biosynthesis. Molecular Biology and Evolution 2007, 24(8) 1714-1721.

Lamb DC, Waterman MR, Kelly SL, Guengerich FP. Cytochromes P450 and drug discovery. Current Opinion in Biotechnology 2007, 18(6) 504-512.

Zhao B, Lamb DC, Lei L, Kelly SL, Yuan H, Hachey DL, Waterman MR. Different binding modes of two flaviolin substrate molecules in cytochrome P450 158A1 (CYP158A1) compared to CYP158A2. Biochemistry 2007, 46(30) 8725-8733.


EllowayEAG, Bird RA, Hewitt CJ, Kelly SL, Smith SN. Characterization of Acanthamoeba-microsphere association by multiparameter flow cytometry and confocal microscopy. Cytometry Part A 2006, 69A (4): 266-272.

Kaderbhai MA, Kelly SL, Kaderbhai, NN. Towards engineered topogenesis of cytochrome b5 and P450 for in vivo transformation of xenobiotics. Biochemical Society Transactions 2006, 34(6), 1159-1160.

Kelly SL, Lamb DC, Kelly DE. Cytochrome P450 biodiversity and biotechnology. Biochemical Society Transactions 2006, 34(6) 1159-60.

Lamb DC, Guengerich FP, Kelly SL, Waterman, MR. Exploiting Streptomyces coelicolor A3(2) P450s as a model for application in drug discovery. Expert Opinion on Drug Metabolism & Toxicology 2006, 2(1) 27-40.

Lamb DC, Kim Y, Yermalitskaya LV, Yermalitsky VN, Lepesheva GI, Kelly SL, Waterman MR, Podust LM. A second FMN binding site in yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron transfer by diflavin reductases. Structure 2006, 14(1) 51-61.

Rupasinghe S, Schuler MA, Kagawa N, Yuan H, Lei L, Zhao B, Kelly SL, Waterman MR, Lamb,DC. The cytochrome P450 gene family CYP157 does not contain EXXR in the K-helix reducing the absolute conserved P450 residues to a single cysteine. FEBS Letters 2006, 580(27) 6338-42.


AkhtarMK, Kelly SL, Kaderbhai MA. Cytochrome b(5) modulation of 17-alpha hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. Journal of Endocrinology 2005, 187(2) 267-274.

Pinjon E, Jackson CJ, Kelly SL, Sanglard D, Moran G, Coleman DC, Sullivan DJ. Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression. Antimicrobial Agents and Chemotherapy 2005, 49(4) 1312-1318.

Zhao B, Guengerich FP, Bellamine A, Lamb DC, Izumikawa M, Lei L, Podust LM, Sundaramoorthy M, Kalaitzis JA, Reddy LM, Kelly SL, Moore BS, Stec D, Voehler M, Falck JR, Shimada T, Waterman MR. Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. Journal of Biological Chemistry 2005, 280(12) 11599-11607.


Elloway EA, Armstrong RA, Bird RA, Kelly SL, Smith SN. Analysis of Acanthamoeba polyphaga surface carbohydrate exposure by FITC-lectin binding and fluorescence evaluation. Journal of Applied Microbiology 2004, 97(6) 1319-1325.

Lei L, Waterman MR, Fulco AJ, Kelly SL, Lamb DC. Availability of specific reductases controls the temporal activity of the cytochrome P450 complement of Streptomyces coelicolor A3(2). Proceedings of the National Academy of Sciences USA 2004, 101(2) 494-499.

Podust LM, Bach H, Kim Y, Lamb DC, Arase M, Sherman DH, Kelly SL, Waterman MR. Comparison of the 1.85 A structure of CYP154A1 from Streptomyces coelicolor A3(2) with the closely related CYP154C1 and CYPs from antibiotic biosynthetic pathways. Protein Science 2004, 13(1) 255-268.

Revankar SG, Fu J, Rinaldi MG, Kelly SL, Kelly DE, Lamb DC, Keller SM, Wickes BL. Cloning and characterization of the lanosterol 14alpha-demethylase (ERG11) gene in Cryptococcus neoformans. Biochemical and Biophysical Research Communications 2004, 324(2) 719-728.

For further publications please see ResearchGate.

Fellow of the Royal Society of Biology
Fellow of the Royal Society of Chemistry
Fellow of the Learned Society of Wales